SCHEMBL29669233

SCHEMBL29669233

ClCc1nccs1.O=S(=O)(O)CCS(=O)(=O)O

nearest known ligand 0.42

Known targets — ChEMBL curated mechanism

DRD2

The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
ACP1 P24666 2/20 0.41
FDPS P14324 1/20 0.41
CYP2C19 P33261 1/20 0.38
SLC6A3 Q01959 3/20 0.35
ALDH1A1 P00352 3/20 0.34
PKM P14618 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP2C9 P11712 1/20 0.34
LMNA P02545 2/20 0.32
GAA P10253 1/20 0.32
TSHR P16473 1/20 0.32
CYP2D6 P10635 1/20 0.32
MAPK1 P28482 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL345097 0.82
Methyl Alcohol SCHEMBL28535540 0.81
Hydrochloric Acid SCHEMBL1121573 0.80
SCHEMBL1412612 0.79 ACP1 (0.41) ACP1FDPSCYP2C19SLC6A3ALDH1A1
Ethane SCHEMBL28789069 0.78
Hydrochloric Acid SCHEMBL28858634 0.77 ACP1 (0.41) ACP1FDPSCYP2C19SLC6A3ALDH1A1
Alcohol SCHEMBL27675013 0.77 FDPS (0.42) FDPSSLC6A3ALDH1A1PKMLMNA
Hydrochloric Acid SCHEMBL28585523 0.76 ACP1 (0.45) ACP1FDPSCYP2C19SLC6A3ALDH1A1
SCHEMBL3093696 0.67 CYP2C19 (0.43) ACP1FDPSCYP2C19SLC6A3ALDH1A1
SCHEMBL27557745 0.67 ACP1 (0.44) ACP1FDPSALDH1A1PKMLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114732910-A P38 kinase inhibitor reduces DUX4 and downstream gene expression for treatment of FSHD 弗尔康医疗公司 2022-07-12 CN disclosed